The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre mRNA and to a region of a second exon within the same pre mRNA wherein said region of said second exon has at least 50% identity with said region of said first exon wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre mRNA and preferably the entire stretch of exons in between.
